Neal D. Shore, MD (he/him/his)

START Carolinas/Carolina Urologic Research Center

Neal Shore, MD, FACS
Start Carolinas Research(formerly Carolina Urologic Research Center)
Myrtle Beach, South Carolina

Neal Shore graduated from Duke University and Duke University Medical School.He completed his general surgery/urology residency at New York Hospital-Cornell Medical Center/Memorial Sloan Kettering Cancer Center. He serves as the Medical Director for the START-Carolina Urologic Research Center as well as the Global Director, GU Oncology START Cancer Research.

Dr. Shore has conducted more than 500 clinical trials, focusing mainly on genitourinary oncology, and has authored more than 400 peer-reviewed publications and numerous book chapters. He serves on the Society for Immunotherapy of Cancer (SITC) Guidelines Committee for Bladder Cancer, as has served on the boards of the Bladder Cancer Advocacy Network,the APCCC Scientific Steering Committee,Maple Tree Cancer Alliance, and the Duke Global Health Institute. He is the Chair of both the Prostate Cancer Academy and the Bladder/Kidney Cancer Academy, and the co-chair of the annual AUA International Prostate Cancer Forum. He has served/serves on the editorial boards of Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE, Urology Practice,JUOP,Everyday Urology Oncology and World Journal of Urology.He is the Editor-in-Chief of Reviews in Urology . He is a Fellow of the American College of Surgeons and a Certified Physician Investigator.

Disclosure information not submitted.

Presentation(s):

• MP11-14: Treatment duration and long-term safety and tolerability with darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC): ARAMIS Rollover Study

  Friday, April 28, 2023
  9:30 AM – 11:30 AM CST

• MP29-02: Efficacy and Safety of Darolutamide in Combination with Androgen-deprivation Therapy and Docetaxel in the North American Population from ARASENS

  Saturday, April 29, 2023
  7:00 AM – 9:00 AM CST

• MP29-05: Treatment Pattern and Health-Related Quality of Life (HRQoL) of Patients (pts) With Metastatic Castration-Resistant Prostate Cancer (mCRPC) in the United States (US)

  Saturday, April 29, 2023
  7:00 AM – 9:00 AM CST

• MP29-13: Real-world Study on Darolutamide, Enzalutamide, and Apalutamide for Nonmetastatic Castration-Resistant Prostate Cancer Patients Using a Urology Network in the United States (DEAR Study)

  Saturday, April 29, 2023
  7:00 AM – 9:00 AM CST

• Session Five: Collaboration with Academic Institutions and International

  Saturday, April 29, 2023
  10:35 AM – 10:37 AM CST

• Q&A with Session Speakers

  Saturday, April 29, 2023
  11:13 AM – 11:20 AM CST

• EMBARK: A Phase 3 Randomized Study of Enzalutamide or Placebo Plus Leuprolide Acetate and Enzalutamide Monotherapy in High-Risk Biochemically Recurrent Prostate Cancer

  Saturday, April 29, 2023
  9:45 AM – 10:00 AM CST

• PD21-11: REAL WORLD IMPACT OF GERMLINE GENETIC TESTING ON CLINICAL DECISION MAKING FOR PROSTATE CANCER PATIENTS

  Saturday, April 29, 2023
  2:30 PM – 2:40 PM CST

• Enhancing the Treatment of High-Risk Non-Muscle Invasive Bladder Cancer With Immunotherapy-Based Regimens

  Saturday, April 29, 2023
  6:00 PM – 8:00 PM CST

• International Prostate Forum Introductions

  Sunday, April 30, 2023
  8:01 AM – 8:05 AM CST

• Challenge VII: Updates in Advanced Prostate Cancer

  Sunday, April 30, 2023
  11:45 AM – 12:45 PM CST

• Optimal TURBT: Do Skilled Urologists Really Need PDD?

  Sunday, April 30, 2023
  2:30 PM – 2:50 PM CST

• Beyond The Guidelines: Urologic Oncology Investigators Provide Perspectives on the Optimal Management of Prostate Cancer

  Sunday, April 30, 2023
  5:30 PM – 8:00 PM CST